BridgeBio Oncology officer reports initial share holdings
BridgeBio Oncology Therapeutics, Inc. executive Marc Cobo, the Principal Accounting Officer, reported his initial ownership position on a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics, Inc. executive Marc Cobo, the Principal Accounting Officer, reported his initial ownership position on a Form 3. He directly holds 5,431 shares of Common Stock, which include 5,227 unvested restricted stock units, each representing a contingent right to receive one share upon vesting.
He also holds stock options covering 25,125 shares of Common Stock at an exercise price of $10.19 per share expiring on March 9, 2036, and options covering 129,090 shares at an exercise price of $9.59 per share expiring on August 25, 2035. These equity awards vest over time, subject to his continuous service with the company.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Cobo Marc
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 154,215 contracts (Direct);
Common Stock — 5,431 shares (Direct)
Footnotes (3)
- F1. Includes 5,227 unvested restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in equal quarterly installments, subject to the Reporting Person's continuous service to the Issuer on each such date, with the final installment scheduled to vest on January 1, 2030. The RSUs will be settled in shares of Common Stock upon vesting.
- F2. 25% of the shares underlying such option shall vest and become exercisable on May 19, 2026, with the remainder vesting and becoming exercisable in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F3. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Common shares held: 5,431 shares
Unvested RSUs: 5,227 units
Option grant 1 underlying shares: 25,125 shares
+3 more
6 metrics
Common shares held
5,431 shares
Direct Common Stock ownership reported on Form 3
Unvested RSUs
5,227 units
Each RSU represents one common share, vesting quarterly through January 1, 2030
Option grant 1 underlying shares
25,125 shares
Stock Option (Right to Buy) at $10.19 exercise price, expiring March 9, 2036
Option grant 1 exercise price
$10.19 per share
Exercise price for 25,125-share stock option grant
Option grant 2 underlying shares
129,090 shares
Stock Option (Right to Buy) at $9.59 exercise price, expiring August 25, 2035
Option grant 2 exercise price
$9.59 per share
Exercise price for 129,090-share stock option grant
Key Terms
restricted stock units, Stock Option (Right to Buy), exercise price, vest, +1 more
5 terms
restricted stock units financial
"Includes 5,227 unvested restricted stock units ("RSUs"), each representing a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" reported with underlying common shares"
exercise price financial
"conversion_or_exercise_price: "10.1900" and "9.5900" for the stock options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"The RSUs vest in equal quarterly installments, subject to the Reporting Person's continuous service"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer on each such date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership did Marc Cobo report on his BridgeBio Oncology (BBOT) Form 3?
Marc Cobo reported direct ownership of 5,431 BridgeBio Oncology common shares. This total includes 5,227 unvested restricted stock units that may convert into shares over time, plus additional stock options giving him rights to acquire more shares if exercised.
How many unvested RSUs does Marc Cobo hold in BridgeBio Oncology (BBOT)?
Marc Cobo holds 5,227 unvested restricted stock units in BridgeBio Oncology. Each RSU represents a contingent right to receive one common share, vesting in equal quarterly installments through January 1, 2030, assuming he remains continuously employed by the company.
What stock options were reported by Marc Cobo in the BBOT Form 3 filing?
Marc Cobo reported two option grants: options over 25,125 shares at a $10.19 exercise price and options over 129,090 shares at a $9.59 exercise price. Both are exercisable for common stock and expire in 2036 and 2035, respectively, subject to vesting schedules.
When do Marc Cobo’s BridgeBio Oncology (BBOT) stock options vest?
One option grant vests 25% on May 19, 2026, with the rest vesting in 36 equal monthly installments. The other vests in 48 substantially equal monthly installments on each monthly anniversary of January 1, 2026, conditioned on his continued service to the company.
How are Marc Cobo’s RSUs in BridgeBio Oncology (BBOT) scheduled to vest?
Marc Cobo’s 5,227 RSUs vest in equal quarterly installments, ending with a final installment on January 1, 2030. Vesting requires his continuous service with BridgeBio Oncology, after which each vested RSU will be settled in one share of common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates